Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
24,683,081

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication

Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.

    Sweta Killa headshot

    Q1 Earnings Drag Pharma ETFs Down

    Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.

      Swarup Gupta headshot

      Dow 30 Stock Roundup: AAPL, DWDP, CVX, MRK, MCD, PFE Beat on Earnings

      The Dow endured a particularly tough week, ending with marginal gains for the first time only on Thursday.

        What's in the Cards for Aerie (AERI) This Earnings Season?

        Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).

          Company News for May 2, 2018

          Companies In The News are: PFE,MRK,THC,BP

            ADP Job Data, Q1 Earnings In Focus

            ADP Job Data, Q1 Earnings In Focus

              Mark Vickery headshot

              Jobs Week Shows New Wage Growth (and Lack Thereof)

              Paychex reported small-business jobs and wage growth for last month, and the results are definitely interesting.

                Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat

                Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.

                  Kinjel Shah headshot

                  Pfizer (PFE) Q1 Earnings Beat, Sales Miss, 2018 View Intact

                  Pfizer (PFE) beat expectations for earnings but missed the same for revenues in Q1. It retained its previously issued guidance for 2018.

                    Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?

                    Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.

                      Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                      Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.

                        Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More

                        Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.

                          McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview

                          McDonald's, Apple, Pfizer, MasterCard and Activision-Blizzard are part of Zacks Earnings Preview

                            Amazon (AMZN) Q1 Earnings Crush Estimates, Sales Surge Y/Y

                            Amazon's (AMZN) first-quarter results benefit from robust revenue growth in the AWS segment.

                              Why Pfizer (PFE) Might Surprise This Earnings Season

                              Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses

                                Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.

                                  What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

                                  During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .

                                    What's in the Offing for Keryx (KERX) This Earnings Season?

                                    Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.

                                      Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings?

                                      With both Merck and Pfizer are scheduled to report on May 1, this may be a good time to figure out which of these is a better stock.

                                        Sweta Killa headshot

                                        Is FlexShares Quality Dividend Defensive Index Fund (QDEF) a Hot ETF Right Now?

                                        Smart Beta ETF report for QDEF

                                          Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

                                          While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

                                            What's in the Cards for Merck (MRK) This Earnings Season?

                                            Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

                                              Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

                                              Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

                                                Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

                                                While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

                                                  The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer

                                                  The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer